Astellas Buys AI‑Designed AAV

Astellas has taken a licensed bet on an artificial-intelligence-designed gene therapy delivery shell built by Dyno Therapeutics for skeletal muscle. (dynotx.com) Dyno said on April 8 that Astellas exercised an option under the companies’ 2021 collaboration, triggering a $15 million license fee plus potential milestone and royalty payments. Trade reporting put the total deal value at up to $1.6 billion. (dynotx.com) (precisionmedicineonline.com) The licensed asset is an adeno-associated virus capsid, the protein coat that acts like a mailing label for where a gene therapy goes in the body. Dyno said this one was engineered for delivery to skeletal muscle, and Astellas will handle preclinical, clinical, regulatory, manufacturing, and commercial work. (biopharminternational.com) (allsci.com) That targeting problem has become central in gene therapy because many muscle programs still rely on older adeno-associated virus types that can require high systemic doses. BioPharm International said those dose levels can raise toxicity risk and make manufacturing harder. (biopharminternational.com) Dyno’s pitch is that machine learning can design better capsids by linking genetic sequence to where the vector actually lands in animals. The company’s CapsidMap platform, first highlighted in the Astellas partnership announcement in December 2021, was built to optimize delivery to skeletal and cardiac muscle. (astellas.com) (biopharminternational.com) Dyno said the selected capsid showed stronger skeletal muscle targeting in non-human primates and could be made with existing manufacturing processes. That matters because muscle disorders often need body-wide delivery, which pushes vector supply and safety limits. (firstwordpharma.com) (dynotx.com) For Astellas, the deal extends a gene therapy push that accelerated after its 2020 acquisition of Audentes Therapeutics and the creation of its Gene Therapies Center of Excellence. The 2021 Dyno alliance was aimed at next-generation vectors for skeletal and cardiac muscle from the start. (astellas.com) For Dyno, this is its second licensed capsid from the platform. Roche exercised an option in January 2025 for a neurological disease program, with a $7 million payment and potential milestones of more than $220 million. (dynotx.com 1) (dynotx.com 2) The immediate test is no longer whether Dyno can generate a partner deal. It is whether Astellas can turn an artificial-intelligence-designed delivery shell into a muscle gene therapy that survives development, manufacturing, and human studies. (allsci.com) (dynotx.com)